Knopp Neurosciences Restructures into Knopp Biosciences

Knopp Neurosciences is restructuring into a new company called Knopp Biosciences. The new structure will allow a continued working relationship with Biogen, which has exclusive development and commercialization rights to Knopp’s drug KNS-760704, a treatment for ALS.

Click here to read more.

Share this: